{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Engesser J"],"funding":["Deutsche Forschungsgemeinschaft","Deutsche Forschungsgemeinschaft (German Research Foundation)"],"pagination":["8220"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11413367"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a life-threatening autoimmune disease that often results in kidney failure caused by crescentic glomerulonephritis (GN). To date, treatment of most patients with ANCA-GN relies on non-specific immunosuppressive agents, which may have serious adverse effects and be only partially effective. Here, using spatial and single-cell transcriptome analysis, we characterize inflammatory niches in kidney samples from 34 patients with ANCA-GN and identify proinflammatory, cytokine-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells as a pathogenic signature. We then utilize these transcriptomic profiles for digital pharmacology and identify ustekinumab, a monoclonal antibody targeting IL-12 and IL-23, as the strongest therapeutic dr"],"journal":["Nature communications"],"pubmed_title":["Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis."],"pmcid":["PMC11413367"],"funding_grant_id":["SFB1192"],"pubmed_authors":["Riedel JH","Huber TB","Asada N","Peters A","Puelles VG","Kaffke A","Wiech T","Krebs CF","Schaub DP","Khatri R","Sivayoganathan V","Panzer U","Wenzel UO","Turner JE","Zhao Y","Goldbeck-Strieder T","Mittrucker HW","Bonn S","Sultana Z","Paust HJ","Steinmetz OM","Jauch-Speer SL","Hoxha E","Engesser J"],"additional_accession":[]},"is_claimable":false,"name":"Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis.","description":"Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a life-threatening autoimmune disease that often results in kidney failure caused by crescentic glomerulonephritis (GN). To date, treatment of most patients with ANCA-GN relies on non-specific immunosuppressive agents, which may have serious adverse effects and be only partially effective. Here, using spatial and single-cell transcriptome analysis, we characterize inflammatory niches in kidney samples from 34 patients with ANCA-GN and identify proinflammatory, cytokine-producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells as a pathogenic signature. We then utilize these transcriptomic profiles for digital pharmacology and identify ustekinumab, a monoclonal antibody targeting IL-12 and IL-23, as the strongest therapeutic dr","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-05-04T06:38:42.329Z","creation":"2025-04-04T08:21:48.951Z"},"accession":"S-EPMC11413367","cross_references":{"pubmed":["39300109"],"doi":["10.1038/s41467-024-52525-w"]}}